[go: up one dir, main page]

MX2008015392A - Tratamiento de enfermedades isquemicas que usan eritropoyetina. - Google Patents

Tratamiento de enfermedades isquemicas que usan eritropoyetina.

Info

Publication number
MX2008015392A
MX2008015392A MX2008015392A MX2008015392A MX2008015392A MX 2008015392 A MX2008015392 A MX 2008015392A MX 2008015392 A MX2008015392 A MX 2008015392A MX 2008015392 A MX2008015392 A MX 2008015392A MX 2008015392 A MX2008015392 A MX 2008015392A
Authority
MX
Mexico
Prior art keywords
subject
erythropoietin
treatment
peripheral blood
ischemical
Prior art date
Application number
MX2008015392A
Other languages
English (en)
Inventor
Toshio Matsumoto
Tetsuya Kitagawa
Masahiro Abe
Masashi Akaike
Kazunari Nagayoshi
Kaname Yamamoto
Masato Higuchi
Original Assignee
Univ Tokushima
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tokushima filed Critical Univ Tokushima
Publication of MX2008015392A publication Critical patent/MX2008015392A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un método para la regeneración vaso sanguíneo, que comprende los pasos de: (a) administrar eritroyetina a un sujeto; (b) recolectar una célula mononuclear de sangre periférica del sujeto; y (c) administrar la célula mononuclear de sangre periférica recolectada a un sitio deseado en el sujeto. Cuando se administra eritropoyetina a un sujeto, se recluta una célula mononuclear de sangre periférica (particularmente una postica a CD34) en la sangre periférica del sujeto. El método es útil para el tratamiento de una enfermedad isquémica tal como trastorno vascular periférico.
MX2008015392A 2006-06-07 2007-06-07 Tratamiento de enfermedades isquemicas que usan eritropoyetina. MX2008015392A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006158998 2006-06-07
PCT/JP2007/061525 WO2007142288A1 (ja) 2006-06-07 2007-06-07 エリスロポエチンを用いた虚血性疾患の治療

Publications (1)

Publication Number Publication Date
MX2008015392A true MX2008015392A (es) 2009-05-05

Family

ID=38801534

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008015392A MX2008015392A (es) 2006-06-07 2007-06-07 Tratamiento de enfermedades isquemicas que usan eritropoyetina.

Country Status (16)

Country Link
US (1) US20090280094A1 (es)
EP (1) EP2047859A4 (es)
JP (2) JP5326079B2 (es)
KR (1) KR20090031547A (es)
CN (1) CN101460188B (es)
AR (1) AR061269A1 (es)
AU (1) AU2007255717B2 (es)
BR (1) BRPI0712063A2 (es)
CA (1) CA2654154A1 (es)
IL (1) IL195648A0 (es)
MX (1) MX2008015392A (es)
NO (1) NO20085098L (es)
NZ (1) NZ573792A (es)
RU (1) RU2008152746A (es)
TW (1) TW200815026A (es)
WO (1) WO2007142288A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2047859A4 (en) * 2006-06-07 2010-05-05 Univ Tokushima TREATMENT OF ISCHEMIC ILLNESS WITH ERYTHROPOETIN
EP3150701B1 (en) 2009-06-05 2018-10-03 FUJIFILM Cellular Dynamics, Inc. Reprogramming t cells and hematopoietic cells
FR2957799B1 (fr) * 2010-03-26 2012-08-17 Inst Des Vaisseaux Et Du Sang Compositions proangiogeniques, leur procede de preparation et leurs utilisations
CN101940590B (zh) * 2010-08-27 2013-09-18 上海士腾生物技术有限公司 促进创伤愈合的制剂及其制备方法
CN101940594B (zh) * 2010-08-27 2013-12-04 上海士腾生物技术有限公司 用于治疗缺血性心血管疾病的制剂及其制备方法
JP5582983B2 (ja) * 2010-11-24 2014-09-03 楠本化成株式会社 水系沈降防止剤
US10130660B2 (en) 2013-06-05 2018-11-20 Seoul National University R&Db Foundation Peripheral blood stem cells with improved angiogenic properties and use thereof
DE102017116204B4 (de) 2017-07-18 2024-06-27 Universität Rostock Verfahren zur Vorhersage der Antwort auf die kardiovaskuläre Regeneration

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62501010A (ja) 1984-12-04 1987-04-23 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド エリトロポエチンの生産方法
US4677195A (en) 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
KR100263845B1 (ko) 1989-10-13 2000-08-16 스튜어트 엘.왓트 에리트로포이에틴 동형체와 그의 제조방법 및 그를 포함하는제약학적 조성물
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
DE19857609A1 (de) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US7304031B2 (en) 2001-10-29 2007-12-04 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
US6784154B2 (en) * 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US20040009908A1 (en) * 2002-07-10 2004-01-15 Stamler Jonathan S. Methods for treating or preventing ischemic injury
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US20050058622A1 (en) * 2002-12-06 2005-03-17 Lyman Stewart D. Methods of using Flt3-Ligand in hematopoietic cell transplantation procedures incorporating nonmyeloablative conditioning regimens
EP1633383A4 (en) * 2003-03-27 2008-05-21 Janssen Pharmaceutica Nv USE OF ERYTHROPOIETIN FOR RE-ESTABLISHMENT FOLLOWING A CEREBRAL ISCHEMIC ACCIDENT
CN1764470A (zh) * 2003-03-27 2006-04-26 詹森药业有限公司 促红细胞生成素在中风康复中的用途
US20040198663A1 (en) * 2003-04-04 2004-10-07 Baker John E. Method of treating cardiac ischemia by using erythropoietin
DE102004063927A1 (de) * 2004-01-23 2005-12-15 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
JP2007217283A (ja) * 2004-03-30 2007-08-30 Niigata Tlo:Kk 血管新生促進剤および血管新生療法
JP2006158998A (ja) 2004-12-02 2006-06-22 Nippon Sheet Glass Co Ltd ロッドの反り選別装置
AU2006278264B2 (en) * 2005-08-05 2012-12-06 Araim Pharmaceuticals, Inc. Tissue protective peptides and uses thereof
EP2047859A4 (en) * 2006-06-07 2010-05-05 Univ Tokushima TREATMENT OF ISCHEMIC ILLNESS WITH ERYTHROPOETIN

Also Published As

Publication number Publication date
EP2047859A1 (en) 2009-04-15
JP5326079B2 (ja) 2013-10-30
EP2047859A4 (en) 2010-05-05
IL195648A0 (en) 2011-08-01
CN101460188B (zh) 2013-09-04
AU2007255717A1 (en) 2007-12-13
AR061269A1 (es) 2008-08-13
WO2007142288A1 (ja) 2007-12-13
BRPI0712063A2 (pt) 2011-12-20
US20090280094A1 (en) 2009-11-12
TW200815026A (en) 2008-04-01
KR20090031547A (ko) 2009-03-26
AU2007255717B2 (en) 2013-07-11
NO20085098L (no) 2009-02-27
JP2013116919A (ja) 2013-06-13
RU2008152746A (ru) 2010-07-20
CN101460188A (zh) 2009-06-17
CA2654154A1 (en) 2007-12-13
JPWO2007142288A1 (ja) 2009-10-29
HK1128419A1 (en) 2009-10-30
NZ573792A (en) 2011-09-30

Similar Documents

Publication Publication Date Title
MX2008015392A (es) Tratamiento de enfermedades isquemicas que usan eritropoyetina.
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
SG170789A1 (en) Treatment of peripheral vascular disease using postpartum-derived cells
Cicha et al. Nano-biomaterials for cardiovascular applications: Clinical perspective
CL2008000594A1 (es) Uso de compuestos derivados de heterociclos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad arterial coronaria entre otras enfermedades.
CY1120888T1 (el) Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντες
SMT201300095B (it) Uso dell'estere etilico dell'acido eicosapentaenoico per trattare l'ipertrigliceridemia
GT201200164A (es) "nuevos compuestos de espiropiperidina"
SV2011003939A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
AR059720A1 (es) Medios para mejorar la salud cardiovascular
CL2008000593A1 (es) Uso de compuestos derivados de heterociclos sustituidos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad aterosclerotica de las arterias entre otras enfermedades.
DK2911754T3 (da) Medicinsk benstøtteindretning beregnet til at øge omfanget af et bens bevægelse for at hjælpe ved heling og styrkelse af beskadigede, sårede og/eller udskiftede knogler, muskler og/eller væv i benet
TN2015000084A1 (fr) Pyridinones bicycliques nouvelles
UY30419A1 (es) Nuevos benzoxazoles heteroaril sustituidos
GT201300047A (es) Tratamiento de hipertension y/o prevencion o tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante
WO2012106367A3 (en) Pluripotent stem cells and method of stimulating and extracting non-embryonic pluripotent stem cells from mammal blood and using reconstituted pluripotent stem cells to treat diseases including chronic obstructive pulmonary disease
ATE395924T1 (de) Wiederherstellung zerstörten gewebes mit hilfe von multipotenten zellen
AR094291A1 (es) Formulacion inyectable de liberacion prolongada que comprende tolvaptan opticamente activo, y un procedimiento para producirla
BR112013032911A2 (pt) leucotoxina e/d como um novo agente anti-inflamatório e microbicida
WO2010091051A3 (en) Therapeutic use of specialized endothelial progenitor cells
AR085141A1 (es) Un metodo para prolongar la supervivencia de un aloinjerto renal, uso de un anticuerpo anti-cd200 para prolongar la supervivencia de aloinjertos
ES2578729T3 (es) Agente terapéutico para enfermedades relacionadas con el hígado
NI201200008A (es) Otamixaban para el tratamiento de pacientes con alteración renal y de edad avanzada con infarto de miocardio sin elevación del st
BRPI1010512A2 (pt) "método ex vivo para avaliar a eficácia de um tratamento envolvendo a administração de uma composição imunogênica a um paciente, e, uso de níveis de linfócitos t ativados (cd3 + cd69+) como um biomarcador"
TH156791A (th) การรักษาโรคหลอดเลือดส่วนปลายโดยใช้เซลล์ที่ได้รับมาจากเนื้อเยื่อสายสะดือ

Legal Events

Date Code Title Description
FG Grant or registration